Many U.S. Communities Vulnerable to HIV Outbreaks Due to Unsafe Opioid Injection

Research published recently in the online edition of the Journal of Acquired Immune Deficiency Syndromes has identified the jurisdictions in the U.S especially vulnerable to the rapid spread of HIV or hepatitis C virus (HCV) due to unsafe injection drug use. A total of 220 countries in 26 states had a high level of vulnerability, with factors associated with unsafe injecting including unemployment, and poverty, and high rates of death due to drug overdose.


AIDS 2016: International AIDS Conference Coming Up in Durban

The 21st International AIDS Conference (AIDS 2016) will take place July 18-22 in Durban, South Africa, 16 years after the groundbreaking conference in the same city that put the spotlight on global access to new life-saving treatment for people living with HIV and AIDS. This year's theme -- Access, Equity, Rights Now -- recognizes the barriers that still need to be overcometo achieve universal access. and collaborator will provide comprehensive on-site coverage starting July 18. Follow @HIVandHepatitison Twitter and see our AIDS 2016 conference page (coming soon) or Facebook page for the latest news.


Coverage of ASM Microbe 2016 (ICAAC 2016) coverage of ASM Microbe 2016 -- a new conference incorporating the American Society for Microbiology annual meeting and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) -- Boston, June 16-20, 2016.

Highlights of this year's conference include antiretroviral drugs and treatment strategies, HIV pre-exposure prophylaxis (PrEP), microbiome research, antibiotic resistance, and emerging viruses including Zika.

Full coverage listing by topic

ASM Microbe 2016 website



AIDS 2016: Second Durban Declaration Highlights Key Advances and Barriers

In advance of the 21st International AIDS Conference (AIDS 2016), starting July 18 in Durban, South Africa, the International AIDS Society has released the Second Durban Declaration, highlighting the 5 key scientific advances in the HIV field and 5 key structural barriers that have yet to be overcome.


ASM Microbe 2016: HIV Seroconversion Is Rare If PrEP Is Used Consistently

New HIV infections occurred at a low rate of about 1 per 100 person-years among people who took Truvada for pre-exposure prophylaxis (PrEP), with seroconversions mostly seen in those who stopped taking their pills, according to an analysis of more than 30 studies and demonstration projects presented last week at the ASM Microbe 2016 conference in Boston.


ASM Microbe 2016: New Integrase Inhibitor Bictegravir Looks Promising in Early Studies

Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favorable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity in laboratory and human studies, according to a set of posters presented at ASM Microbe 2016 last month in Boston.


ASM Microbe 2016: Atripla 3 Times Weekly Maintains HIV Viral Suppression

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for 6 months, and longer follow-up is planned, according to research presented last week at the ASM Microbe conference in Boston.